Altimmune ALT Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$91.08M-0.9% | -$88.09M+7.3% | -$83.92M+18.9% | -$87.75M+13.4% | -$90.24M+2.7% | ||
| $106K-33.8% | $112K-52.9% | $119K-94.3% | $129K-91.4% | $160K-83.0% | ||
| $15.44M+4.6% | $16.08M+11.7% | $14.49M+7.3% | $14.01M+6.6% | $14.76M+27.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $1.16M— | $675K— | —— | —— | —— | ||
| —— | —— | —— | —— | -$2.68M-81.5% | ||
| $1.6M— | $2.39M— | —— | —— | —— | ||
| —— | —— | $1.11M— | $874K— | -$593K— | ||
| -$71.64M+10.8% | -$67.54M+15.4% | -$66.35M+15.1% | -$81.57M-14.1% | -$80.33M-10.4% | ||
| —— | —— | —— | —— | —— | ||
| $285.6M+171% | $285.45M+147% | $210.11M+54.1% | $86.59M-29.1% | $105.35M-12.9% | ||
| $154.57M+38.8% | $152.99M+75.2% | $170.43M+97.3% | $197.43M+162% | $111.39M+36.1% | ||
| -$131.06M— | -$132.47M— | —— | —— | —— | ||
| $147.73M+230% | $173.73M+1,638% | $121.74M+66.6% | $82.36M+12.1% | $44.73M-48.3% | ||
| $726K-21.8% | $709K-16.6% | $686K-22.5% | $690K-21.9% | $928K+41.9% | ||
| —— | —— | —— | —— | —— | ||
| $251.2M+465% | $206.84M+1,959% | $135.8M+86.8% | $96.71M+32.4% | $44.42M-48.4% | ||
| -$329K-563% | -$160K-433% | $1K+102% | $99K+268% | $71K-44.5% | ||
| —— | —— | —— | $120.53M+367% | -$35.33M-37.4% | ||
| —— | —— | —— | —— | —— | ||
| $2.41M-32.2% | $2.22M-42.2% | $2.13M-42.8% | $2.92M-14.7% | $3.55M+19.5% | ||
| —— | —— | —— | —— | —— | ||
| $106K-33.8% | $112K-52.9% | $119K-62.7% | $129K-67.7% | $160K-65.1% | ||
| —— | —— | —— | —— | —— | ||
| $1.6M— | $2.39M— | —— | —— | —— | ||
| -$1.96M— | -$2.74M— | -$3.05M— | —— | —— | ||
| —— | —— | $1.11M— | $874K— | -$593K— | ||
| $154.57M+38.8% | $152.99M+75.2% | $170.43M+97.3% | $197.43M+162% | $111.39M+36.1% | ||
| $402K— | $438K— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Altimmune generate?
- Altimmune (ALT) generated -$71.6M in operating cash flow over the trailing twelve months.
- What is Altimmune's free cash flow?
- After $111.0K of capital expenditures, Altimmune's free cash flow was -$68.8M over the trailing twelve months, up 10.2% year over year.
- Where does Altimmune's cash flow data come from?
- Every line is extracted from Altimmune's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
